{"id":"https://openalex.org/W2588080321","doi":"https://doi.org/10.2147/dddt.s125459","title":"Pharmacokinetics of conivaptan use in patients with severe hepatic impairment","display_name":"Pharmacokinetics of conivaptan use in patients with severe hepatic impairment","publication_year":2017,"publication_date":"2017-02-01","ids":{"openalex":"https://openalex.org/W2588080321","doi":"https://doi.org/10.2147/dddt.s125459","mag":"2588080321","pmid":"https://pubmed.ncbi.nlm.nih.gov/28243060","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5315214"},"language":"en","primary_location":{"id":"doi:10.2147/dddt.s125459","doi":"https://doi.org/10.2147/dddt.s125459","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dddt.s125459","pdf_url":"https://www.dovepress.com/getfile.php?fileID=34870","source":{"id":"https://openalex.org/S2496126384","display_name":"Drug Design Development and Therapy","issn_l":"1177-8881","issn":["1177-8881"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Design, Development and Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/getfile.php?fileID=34870","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028366409","display_name":"Thomas C Marbury","orcid":"https://orcid.org/0000-0002-6416-3314","observed_orcids":["https://orcid.org/0000-0002-6416-3314"]},"institutions":[{"id":"https://openalex.org/I4210087159","display_name":"Orlando Clinical Research Center","ror":"https://ror.org/000x1tr98","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210087159"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Marbury","raw_affiliation_strings":["Orlando Clinical Research Center, Inc., Orlando, FL"],"raw_orcid":"https://orcid.org/0000-0002-6416-3314","affiliations":[{"raw_affiliation_string":"Orlando Clinical Research Center, Inc., Orlando, FL","institution_ids":["https://openalex.org/I4210087159"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076679584","display_name":"Jerry Fox","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152386","display_name":"Cumberland Pharmaceuticals (United States)","ror":"https://ror.org/04raazs21","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152386"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jerry Fox","raw_affiliation_strings":["Department of Research and Development, Cumberland Pharmaceuticals, Inc., Nashville, TN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Research and Development, Cumberland Pharmaceuticals, Inc., Nashville, TN, USA","institution_ids":["https://openalex.org/I4210152386"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060305338","display_name":"Byron Kaelin","orcid":"https://orcid.org/0000-0001-5278-4749","observed_orcids":["https://orcid.org/0000-0001-5278-4749"]},"institutions":[{"id":"https://openalex.org/I4210152386","display_name":"Cumberland Pharmaceuticals (United States)","ror":"https://ror.org/04raazs21","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152386"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Byron Kaelin","raw_affiliation_strings":["Department of Research and Development, Cumberland Pharmaceuticals, Inc., Nashville, TN, USA"],"raw_orcid":"https://orcid.org/0000-0001-5278-4749","affiliations":[{"raw_affiliation_string":"Department of Research and Development, Cumberland Pharmaceuticals, Inc., Nashville, TN, USA","institution_ids":["https://openalex.org/I4210152386"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001038485","display_name":"Leo Pavliv","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152386","display_name":"Cumberland Pharmaceuticals (United States)","ror":"https://ror.org/04raazs21","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152386"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leo Pavliv","raw_affiliation_strings":["Department of Research and Development, Cumberland Pharmaceuticals, Inc., Nashville, TN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Research and Development, Cumberland Pharmaceuticals, Inc., Nashville, TN, USA","institution_ids":["https://openalex.org/I4210152386"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5076679584"],"corresponding_institution_ids":["https://openalex.org/I4210152386"],"apc_list":{"value":2836,"currency":"USD","value_usd":2836},"apc_paid":{"value":2836,"currency":"USD","value_usd":2836},"fwci":0.9675,"has_fulltext":true,"cited_by_count":10,"citation_normalized_percentile":{"value":0.73994541,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":96},"biblio":{"volume":"Volume11","issue":null,"first_page":"373","last_page":"382"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11967","display_name":"Electrolyte and hormonal disorders","score":0.986299991607666,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11967","display_name":"Electrolyte and hormonal disorders","score":0.986299991607666,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.004800000227987766,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/conivaptan","display_name":"conivaptan","score":1.0},{"id":"https://openalex.org/keywords/vasopressin-receptor-antagonists","display_name":"vasopressin receptor antagonists","score":0.781000018119812},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9340000152587891},{"id":"https://openalex.org/keywords/dose-adjustment","display_name":"dose adjustment","score":0.6790000200271606},{"id":"https://openalex.org/keywords/hyponatremia","display_name":"hyponatremia","score":0.9520000219345093},{"id":"https://openalex.org/keywords/protein-binding","display_name":"protein binding","score":0.7450000047683716},{"id":"https://openalex.org/keywords/renal-clearance","display_name":"renal clearance","score":0.5350000262260437},{"id":"https://openalex.org/keywords/elimination-half-life","display_name":"elimination half-life","score":0.6629999876022339},{"id":"https://openalex.org/keywords/child-pugh-score","display_name":"Child-Pugh score","score":0.7039999961853027},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5699999928474426}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7884777188301086},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7161040306091309},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6333666443824768},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5879967212677002},{"id":"https://openalex.org/C2776703092","wikidata":"https://www.wikidata.org/wiki/Q824292","display_name":"Hyponatremia","level":2,"score":0.583019495010376},{"id":"https://openalex.org/C2777075537","wikidata":"https://www.wikidata.org/wiki/Q929737","display_name":"Liver disease","level":2,"score":0.49187517166137695},{"id":"https://openalex.org/C2992208098","wikidata":"https://www.wikidata.org/wiki/Q1359801","display_name":"Liver function","level":2,"score":0.4586579203605652},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4160591959953308},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.4056287705898285},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.32182037830352783}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001552","descriptor_name":"Benzazepines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D001552","descriptor_name":"Benzazepines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001552","descriptor_name":"Benzazepines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001552","descriptor_name":"Benzazepines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007275","descriptor_name":"Injections, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008107","descriptor_name":"Liver Diseases","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008107","descriptor_name":"Liver Diseases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D008107","descriptor_name":"Liver Diseases","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":6,"locations":[{"id":"doi:10.2147/dddt.s125459","doi":"https://doi.org/10.2147/dddt.s125459","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dddt.s125459","pdf_url":"https://www.dovepress.com/getfile.php?fileID=34870","source":{"id":"https://openalex.org/S2496126384","display_name":"Drug Design Development and Therapy","issn_l":"1177-8881","issn":["1177-8881"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Design, Development and Therapy","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:4179565","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5315214","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:5315214","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5315214","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Des Devel Ther","raw_type":"Text"},{"id":"pmid:28243060","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28243060","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug design, development and therapy","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:doaj.org/article:81216a37a7314b4287532f2fa2173922","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/81216a37a7314b4287532f2fa2173922","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Drug Design, Development and Therapy, Vol Volume11, Pp 373-382 (2017)","raw_type":"article"},{"id":"pmh:oai:dovepress.com/31275","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/pharmacokinetics-of-conivaptan-use-in-patients-with-severe-hepatic-imp-peer-reviewed-article-DDDT","pdf_url":null,"source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.2147/dddt.s125459","doi":"https://doi.org/10.2147/dddt.s125459","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dddt.s125459","pdf_url":"https://www.dovepress.com/getfile.php?fileID=34870","source":{"id":"https://openalex.org/S2496126384","display_name":"Drug Design Development and Therapy","issn_l":"1177-8881","issn":["1177-8881"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Design, Development and Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320310421","display_name":"Cumberland Pharmaceuticals","ror":"https://ror.org/04raazs21"},{"id":"https://openalex.org/F4320323024","display_name":"Astellas Pharma","ror":"https://ror.org/01cjash87"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2588080321.pdf","grobid_xml":"https://content.openalex.org/works/W2588080321.grobid-xml"},"referenced_works_count":12,"referenced_works":["https://openalex.org/W1967812386","https://openalex.org/W1979380304","https://openalex.org/W1994267445","https://openalex.org/W1999694815","https://openalex.org/W2001139960","https://openalex.org/W2002682440","https://openalex.org/W2011813751","https://openalex.org/W2072402970","https://openalex.org/W2080685753","https://openalex.org/W2114676903","https://openalex.org/W2135149679","https://openalex.org/W4294554863"],"related_works":["https://openalex.org/W2001139960","https://openalex.org/W2077880120","https://openalex.org/W2120507043","https://openalex.org/W2007636486","https://openalex.org/W2269624746","https://openalex.org/W1996257503","https://openalex.org/W2042404612","https://openalex.org/W3037821464","https://openalex.org/W2068904135","https://openalex.org/W4308649923"],"abstract_inverted_index":{"PURPOSE:":[0],"vasopressin":[1],"antagonist":[2],"approved":[3],"for":[4,123,263],"the":[5,29,54,258],"treatment":[6],"of":[7,45,60,63,227],"euvolemic":[8],"and":[9,58,84,126,133,182,204,245],"hypervolemic":[10],"hyponatremia.":[11],"Earlier":[12],"studies":[13],"showed":[14],"that":[15],"patients":[16,34,235,264],"with":[17,25,35,68,77,87,160,189,209,236,265],"moderate":[18],"liver":[19,89,162,191,267],"disease":[20],"could":[21],"be":[22],"safely":[23],"treated":[24],"conivaptan":[26,64,94,210,216,259],"by":[27,31,109,223,234,242],"reducing":[28],"dose":[30,41,104,218,260],"50%,":[32],"whereas":[33],"mild":[36],"hepatic":[37,70,79,238],"impairment":[38,80,239],"needed":[39],"no":[40],"adjustment.":[42],"The":[43],"objective":[44],"this":[46],"Phase":[47],"1,":[48],"open-label":[49],"study":[50],"was":[51,97,151,167,184,196,231],"to":[52,158,177],"assess":[53],"pharmacokinetics,":[55],"protein":[56],"binding,":[57],"safety":[59],"48":[61],"h":[62,118],"infusion":[65],"in":[66,128,154,170,187,198,257],"individuals":[67,156],"severe":[69,78,237,266],"impairment.":[71,268],"PATIENTS":[72],"AND":[73],"METHODS:":[74],"Eight":[75],"subjects":[76,86,172,179,188],"(Child-Pugh":[81],"score":[82],"10-15)":[83],"nine":[85],"normal":[88,161,178,190],"function":[90],"were":[91,121,137,143],"enrolled.":[92],"Intravenous":[93],"(20":[95],"mg)":[96],"given":[98,219],"as":[99,175,240],"a":[100,254],"30":[101],"min":[102,221],"loading":[103,217],"on":[105,250],"Day":[106,147],"1":[107],"followed":[108,144,222],"two":[110,224],"consecutive":[111],"20":[112,214,228],"mg":[113,215,229],"continuous":[114],"infusions":[115,226],"over":[116],"24":[117],"each.":[119],"Subjects":[120,142],"monitored":[122,241],"adverse":[124,243],"events":[125,244],"changes":[127],"clinical":[129,246],"laboratory":[130,247],"parameters.":[131],"Plasma":[132],"urine":[134],"pharmacokinetic":[135,251],"samples":[136],"collected":[138],"at":[139],"defined":[140],"times.":[141],"through":[145],"Study":[146],"5.":[148],"RESULTS:":[149],"),":[150],"~60%":[152],"higher":[153,186,197],"impaired":[155,171,199],"compared":[157,176],"those":[159],"function.":[163],"Terminal":[164],"elimination":[165],"half-life":[166],"slightly":[168],"longer":[169],"(12":[173],"h)":[174],"(9":[180],"h),":[181],"clearance":[183],"65%":[185],"function,":[192],"while":[193],"urinary":[194],"excretion":[195],"individuals.":[200],"Albumin":[201],"levels":[202],"directly,":[203],"alkaline":[205],"phosphatase":[206],"inversely,":[207],"correlated":[208],"clearance.":[211],"CONCLUSION:":[212],"A":[213],">30":[220],"daily":[225],"each":[230],"well":[232],"tolerated":[233],"values.":[248],"Based":[249],"data,":[252],"however,":[253],"50%":[255],"reduction":[256],"is":[261],"recommended":[262]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2018,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-02-24T00:00:00"}